Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe Sells 375 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 375 shares of the stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $34.00, for a total transaction of $12,750.00. Following the sale, the senior vice president now directly owns 2,426 shares in the company, valued at $82,484. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Mirum Pharmaceuticals Stock Performance

MIRM opened at $33.88 on Friday. The firm’s fifty day simple moving average is $27.39 and its two-hundred day simple moving average is $27.31. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -9.13 and a beta of 1.15. The company has a quick ratio of 3.47, a current ratio of 3.68 and a debt-to-equity ratio of 1.31. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $35.56.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, May 8th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.14). The business had revenue of $69.22 million during the quarter, compared to analyst estimates of $69.71 million. Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its position in shares of Mirum Pharmaceuticals by 18.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 266,681 shares of the company’s stock valued at $7,872,000 after buying an additional 42,110 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Mirum Pharmaceuticals by 672.9% in the fourth quarter. California State Teachers Retirement System now owns 211,111 shares of the company’s stock valued at $6,232,000 after buying an additional 183,798 shares during the last quarter. CenterBook Partners LP raised its position in shares of Mirum Pharmaceuticals by 242.4% in the fourth quarter. CenterBook Partners LP now owns 51,837 shares of the company’s stock valued at $1,530,000 after buying an additional 36,699 shares during the last quarter. Polar Capital Holdings Plc increased its position in Mirum Pharmaceuticals by 27.0% during the third quarter. Polar Capital Holdings Plc now owns 1,175,000 shares of the company’s stock worth $37,130,000 after purchasing an additional 250,000 shares during the last quarter. Finally, TD Asset Management Inc acquired a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $1,387,000.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on MIRM shares. HC Wainwright reissued a “buy” rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Friday, June 28th. SVB Leerink lowered their price target on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a report on Monday, March 18th. Citigroup increased their price target on shares of Mirum Pharmaceuticals from $38.00 to $64.00 and gave the stock a “buy” rating in a report on Tuesday, June 18th. Baird R W raised shares of Mirum Pharmaceuticals to a “strong-buy” rating in a report on Monday, June 17th. Finally, JMP Securities increased their price target on shares of Mirum Pharmaceuticals from $66.00 to $68.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 18th. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $53.64.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.